市场调查报告书
商品编码
1308630
2030 年生物可吸收聚合物市场预测:按产品类型、应用和地区划分的全球分析Bioresorbable Polymers Market Forecasts to 2030 - Global Analysis By Product Type, Application, and By Geography |
根据Stratistics MRC 的数据,2023 年全球生物可吸收聚合物市场规模将达到15.2 亿美元,预测期内復合年增长率为15.7%,到2030 年将达到42 亿美元。预计将达到3000万美元。
生物可吸收聚合物是医疗行业中常用的物质,因为它们可以被人体安全吸收。 一旦这些聚合物被植入体内,就不需要剥落。 另外,生物可吸收聚合物在医疗行业中的使用会降解生物可吸收聚合物,例如聚乳酸(PLA)、聚乙交酯(PGA)和PLA/PGA的共聚物。 对于将非结构化药物输送到可吸收螺钉和锚钉中,这些材料可以根据机械性能和吸收率进行定制,这将推动市场增长。
推动生物可吸收聚合物市场扩张的主要因素之一是许多外科手术的有利报销情况。 例如,CMS USA 提供全球手术套餐,旨在支付所有手术护理费用,包括外科医生为美国公民提供的术前、术中和术后护理。 因此,由于保险覆盖范围的扩大导致外科手术数量不断增加,预计未来几年生物可吸收聚合物的市场发展将会增长。
由于该领域的发展,基于生物可吸收材料的医疗产品的技术前景和应用正在迅速发展。 这要求医生和其他医疗保健专业人员具备管理由生物可吸收材料製成的药物的必要技能。 因此,外科医生和医疗服务医生不使用复杂的生物可吸收医疗产品来闭合伤口。
聚合物通过实现循环给药、固定剂量治疗剂的时间控制释放以及亲水性和疏水性药物的差异释放,极大地改进了药物递送技术。 自早期使用传统材料以来,该领域已经取得了长足的进步。 现代药物输送领域的突破现在建立在针对特定货物的聚合物的合理设计之上,旨在发挥独特的生物活性。 生物可吸收聚合物能够用配体进行表面修饰,从而实现隐私和人体内的靶向药物输送。 它还允许受控释放到所需位置、对不平衡分子(例如蛋白质)稳定以及对不平衡分子稳定。
与可降解聚合物和其他聚合物相比,生物可吸收聚合物的市场在很大程度上受到其高成本的限制。 儘管预计该市场将以更快的速度发展,但与传统聚合物市场相比仍然很小。 因此,传统聚合物的生产受益于规模经济,而生物可吸收聚合物的生产规模较小。 结果,製造成本增加并且对成品的需求增加。 然而,生物可吸收聚合物仅需要一次性处理,从而改善了整体服务。 从长远来看,此类聚合物高成本的影响是可以减轻的。
鼠疫流行几乎影响着文明的各个方面。 由于全球供应链中断和规划流程延迟,生物可吸收聚合物市场经历了放缓。 医疗行业需求下降是这个问题的根源。 原材料供应短缺,货物到达目的地需要很长时间。 然而,随着医疗和製药领域对生物可吸收聚合物的需求增加,市场开始復苏。 疫情期间医疗行业继续运转,支撑了全球市场。 2021 年开展广泛的疫苗接种运动后,更多发展中国家扩大了生物可吸收聚合物的生产。
聚乳酸部分由于其优异的加工性能和机械强度而预计将获得利润丰厚的增长,使 PLA 成为最具商业可行性的生物聚合物之一。 PLA 无毒、可生物降解、可回收、可堆肥并可被生物体代谢。 它们在许多方面都优于传统聚合物,例如改进的热加工性和各种成型工艺的可能性。 PLA 的两个主要亚型是 PLLA 和 PDLLA。
预计骨科器械设备领域在预测期内復合年增长率最高。 这一应用的高速增长是由于骨科疾病的患病率不断增加、人均收入增加导致生活水平不断提高、医疗保健支出不断增加、世界各国对更优质医疗保健和生物可吸收支架的需求不断增加。多种因素,包括人们认识的提高
由于新兴市场经济快速扩张和人均可支配收入不断上升,亚太地区预计将在预测期内占据最大的市场份额。 印度、中国和日本等高增长国家、人口迅速老龄化、医院数量不断增加、支持性报销政策、有利的政府举措的实施、人均收入的上升以及对卫生部门的重大贡献。尖端外科产品以及私立医院向农村地区的扩张是推动亚太地区市场的其他因素。
由于骨科和药物输送应用中的产品使用量增加,预计北美在预测期内将呈现最高的复合年增长率。 北美生物可吸收聚合物市场受到医疗领域重要研发中心美国的进一步刺激。 此外,骨科和药物输送应用对聚合物的需求不断增长以及医疗支出的增加预计将推动该地区的产品需求。
2023年6月,赢创将在新加坡建造一座新工厂,以在全球范围内拓展其醇盐业务。 未来,醇盐催化剂也将通过在PET塑料的化学回收中的使用,在循环经济中发挥重要作用。
According to Stratistics MRC, the Global Bioresorbable Polymers Market is accounted for $1.52 billion in 2023 and is expected to reach $4.23 billion by 2030 growing at a CAGR of 15.7% during the forecast period. Bioresorbable polymers are substance that is frequently utilised in the healthcare industry because it may be safely absorbed by the body. When these polymers are planted on the body, they do not need to be dethatched. Moreover, the utilization of the Bioresorbable polymers in the healthcare industry breaks down bioresorbable polymers such polylactide (PLA), polyglycolide (PGA), and copolymers of PLA/PGA. For the non-structural drug delivery to resorbable screws and anchors, these materials may be customised to match mechanical performance and resorption rates which drive the growth of the market.
One of the main factors propelling the expansion of the bioresorbable polymers market is the favourable reimbursement status for a number of surgical procedures. For instance, the US CMS offers the worldwide surgical package, which aims to cover payments for all surgical treatments which includes preoperative, intraoperative, and postoperative carried out by surgeons for US citizens. As a result, the market for bioresorbable polymers is anticipated to develop over the next few years as a result of the rising number of surgical operations brought on by better insurance coverage.
Due to developments in this area, the technical landscape and applications for medical goods based on bioresorbable materials are developing quickly. This urges doctors and other healthcare professionals to have the skills necessary to manage medicinal goods made of bioresorbable materials. As a result, sophisticated bioresorbable medical items are not used for wound closure by medical surgeons or doctors from healthcare services.
By permitting cyclic dosing, controlled release of therapeutic agents in constant amounts throughout time, and different releases of both hydrophilic and hydrophobic medications, polymers have considerably improved drug delivery technology. Since its early days of using ordinary materials, the field has substantially grown. Modern breakthroughs in drug delivery are now built on the rational design of polymers intended to exert unique biological activities and tailored for a particular cargo. Bioresorbable polymers have the capacity to change surfaces with ligands for privacy and targeted drug administration in the human body. They also allow regulated release to the desired place, stability to unbalanced molecules (such as proteins), and stability to imbalanced molecules.
The market for bioresorbable polymers is severely constrained by the higher cost of bioresorbable polymers compared to degradable and other polymers. Although the market anticipates a faster pace of development, it is still smaller than the market for traditional polymers. As a result, the manufacturing of traditional polymers benefits from economies of scale, whereas the production of bioresorbable polymers is small-scale. As a result, the cost of production is greater, boosting demand for the finished product. Bioresorbable polymers, however, provide a one-time fix and improved services overall. Long-term, this can lessen the impact of these polymers' greater cost.
The epidemic has had an impact on almost every facet of civilization. The market for bioresorbable polymers has seen a downturn as a result of the interruptions in the global supply chain and the delays in planned processes. The medical industry's declining demand was the root of this problem. Raw resources were scarce, and it took longer for goods to get where they were going. But when the demand for bioresorbable polymers was raised in the medical and pharmaceutical sectors, the market for them began to rebound. The medical sector continued to function during the epidemic, supporting the world market. Following the start of the widespread vaccination campaign in 2021, additional developing countries expanded the manufacture of bioresorbable polymers.
The polylactic acid segment is estimated to have a lucrative growth, due to its excellent process ability and mechanical strength, PLA is one of the most commercially viable biopolymers. PLA is non-toxic, biodegradable, recyclable, compostable, and is metabolised by living things. It is superior to conventional polymers in a number of ways, including improved thermal processability and the ability to be processed through a variety of moulding processes. The two primary subtypes of PLA are PLLA and PDLLA.
The orthopedic devices segment is anticipated to witness the highest CAGR growth during the forecast period, due to the major use of resorbable polymers is in orthopaedics. The high growth in this application is attributed to a number of factors, including an increase in the prevalence of orthopaedic disorders, an improvement in standard of living brought on by rising per capita income, rising healthcare spending, a rise in the demand for higher quality medical care, and increased awareness of bioresorbable stents in numerous nations around the world.
Asia Pacific is projected to hold the largest market share during the forecast period owing to the rapid economic expansion of developing nations and rising per capita disposable income. The presence of high-growth economies like India, China, and Japan, as well as the quick ageing of the population, the rising number of hospitals, supportive reimbursement policies, the implementation of helpful government initiatives, rising per capita income, significant investments in the healthcare sector, demand for cutting-edge surgery products, and the expansion of private hospitals into rural areas are additional factors driving the market in APAC.
North America is projected to have the highest CAGR over the forecast period, owing to rising product use in orthopaedics and medication delivery applications. The bioresorbable polymers market in North America is further fueled by the U.S., which serves as a significant centre for research and development in the healthcare sector. Additionally, it is anticipated that the expanding need for polymers in orthopaedics and drug delivery applications, together with rising healthcare spending, would drive up demand for the product in the area the expanding need for polymers in orthopaedics and drug delivery applications, as well as more healthcare spending, are all expected to drive up product demand in this region.
Some of the key players profiled in the Bioresorbable Polymers Market include Evonik Industries AG, Foster Corporation, Ashland Global Holdings Inc., REVA Medical, LLC, Bezwada Biomedical, LLC, BMG Incorporated, Foryou Medical Devices Co., Ltd, Musashino Chemical Laboratory, Ltd., Henan Xinghan Biotechnology Co. Ltd., KLS Martin Group, DSM Biomedical, Corbion N.V., Zeus Industrial Products, Abbott, 3D Biotek LLC, Sunstar Suisse S.A. and Futerro
In June 2023, Evonik launches new TEGO® Rad 2550 slip and defoamer additive for radiation-curing inks and coatings, The new TEGO® Rad 2550 is a clear, low viscosity liquid that effectively reduces static and dynamic surface tension in both conventional UV- and LED-cured formulations.
In June 2023, Evonik expands global alkoxides business with new Singapore plant. In future, alkoxide catalysts will also play a bigger role in the circular economy through their use in the chemical recycling of PET plastics.